ASU-UA-TGEN Startup Iluminos Licenses Treatment for Alzheimer’s Disease

 

Iluminos Therapeutics has licensed new compounds designed to treat neurodegenerative diseases, particularly Alzheimer’s. Travis Dunckley, PhD, Assistant Research Professor at the ASU-Banner Neurodegenerative Disease Research Center helped develop the new therapies with lead inventor, Christopher Hulme, PhD, Professor of Medicinal Chemistry in the UA Department of Pharmacy and Toxicology (formerly at Eli Lilly and Amgen) and Arthur Shaw, post-doctoral research fellow at the time. The compounds were designed and synthesized at the University of Arizona (UA) College of Pharmacy, in collaboration with the Translational Genomics Research Institute (TGEN).Continue reading

LipimetiX Development Announces Sub-License of Apo E Mimetic Peptide Platform to Anji Pharma, China

LipimetiX Development, Inc. (“LipimetiX” or “the Company”) announced, on May 7, 2018, that Anji Pharmaceuticals, Inc. (“Anji Pharma”) has entered a licensing agreement for the LipimetiX platform of peptides (AEM-28 and analogs) for development of these drug candidates in commercial indications in mainland China, Taiwan and Hong Kong. Anji Pharma’s mission is to license and develop promising therapeutic technologies that address under-served markets in China. LipimetiX is approximately 60%-owned by Capstone Therapeutics Corp. (OTCQB:CAPS).Continue reading

UA Leading the Way in Precision Medicine

Precision medicine is one of the fastest growing fields of medicine, turning the “one-size fits all” approach of healthcare on its head. Precision medicine is a specialized area of medicine that integrates genetic and genomic knowledge with data on environmental and lifestyle influences to individualize and refine care of patients and populations.Continue reading